

Mariana Castanheira

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7241209/publications.pdf>

Version: 2024-02-01

298
papers

17,526
citations

11651
70
h-index

21540
114
g-index

301
all docs

301
docs citations

301
times ranked

12399
citing authors

#	ARTICLE	IF	CITATIONS
1	Simultaneous Emergence of Multidrug-Resistant <i>Candida auris</i> on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses. <i>Clinical Infectious Diseases</i> , 2017, 64, 134-140.	5.8	1,099
2	Increasing Echinocandin Resistance in <i>Candida glabrata</i> : Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations. <i>Clinical Infectious Diseases</i> , 2013, 56, 1724-1732.	5.8	638
3	<i>Escherichia coli</i> Sequence Type ST131 as the Major Cause of Serious Multidrug-Resistant <i>E. coli</i> Infections in the United States. <i>Clinical Infectious Diseases</i> , 2010, 51, 286-294.	5.8	457
4	Twenty Years of the SENTRY Antifungal Surveillance Program: Results for <i>Candida</i> Species From 1997–2016. <i>Open Forum Infectious Diseases</i> , 2019, 6, S79-S94.	0.9	456
5	CLSI Methods Development and Standardization Working Group Best Practices for Evaluation of Antimicrobial Susceptibility Tests. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	372
6	Frequency of Decreased Susceptibility and Resistance to Echinocandins among Fluconazole-Resistant Bloodstream Isolates of <i>Candida glabrata</i> . <i>Journal of Clinical Microbiology</i> , 2012, 50, 1199-1203.	3.9	318
7	Early Dissemination of NDM-1- and OXA-181-Producing <i>Enterobacteriaceae</i> in Indian Hospitals: Report from the SENTRY Antimicrobial Surveillance Program, 2006-2007. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1274-1278.	3.2	303
8	Rapid Detection and Identification of Metallo- β -Lactamase-Encoding Genes by Multiplex Real-Time PCR Assay and Melt Curve Analysis. <i>Journal of Clinical Microbiology</i> , 2007, 45, 544-547.	3.9	259
9	Extended-spectrum β -lactamases: an update on their characteristics, epidemiology and detection. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab092.	2.1	256
10	Molecular Characterization of a β -Lactamase Gene, bla GIM-1 , Encoding a New Subclass of Metallo- β -Lactamase. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 4654-4661.	3.2	236
11	Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008–2010). <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 73, 354-360.	1.8	222
12	<i>Candida</i> bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008–2009). <i>International Journal of Antimicrobial Agents</i> , 2011, 38, 65-69.	2.5	216
13	Echinocandin and Triazole Antifungal Susceptibility Profiles for Clinical Opportunistic Yeast and Mold Isolates Collected from 2010 to 2011: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values for Characterization of Geographic and Temporal Trends of Antifungal Resistance. <i>Journal of Clinical Microbiology</i> , 2013, 51, 2571-2581.	3.9	209
14	<i>Candida</i> Bloodstream Infections: Comparison of Species Distributions and Antifungal Resistance Patterns in Community-Onset and Nosocomial Isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 561-566.	3.2	204
15	First Report of <i>cofA</i> -Mediated Resistance to Linezolid in Human Staphylococcal Clinical Isolates Recovered in the United States. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2244-2246.	3.2	203
16	Geographic Variations in Species Distribution and Echinocandin and Azole Antifungal Resistance Rates among <i>Candida</i> Bloodstream Infection Isolates: Report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). <i>Journal of Clinical Microbiology</i> , 2011, 49, 396-399.	3.9	192
17	Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible <i>Pseudomonas aeruginosa</i> collected during 2009-11 in 14 European and Mediterranean countries. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1804-1814.	3.0	173
18	Contemporary Diversity of β -Lactamases among <i>Enterobacteriaceae</i> in the Nine U.S. Census Regions and Ceftazidime-Avibactam Activity Tested against Isolates Producing the Most Prevalent β -Lactamase Groups. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 833-838.	3.2	170

#	ARTICLE	IF	CITATIONS
19	Variation in <i>Candida</i> spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008–2009). <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 68, 278-283.	1.8	141
20	Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	141
21	Emergence and widespread dissemination of OXA-23, -24/40 and -58 carbapenemases among <i>Acinetobacter</i> spp. in Asia-Pacific nations: report from the SENTRY Surveillance Program. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 63, 55-59.	3.0	139
22	Antimicrobial Susceptibility of <i>Acinetobacter calcoaceticus</i> – <i>Acinetobacter baumannii</i> Complex and <i>Stenotrophomonas maltophilia</i> Clinical Isolates: Results From the SENTRY Antimicrobial Surveillance Program (1997–2016). <i>Open Forum Infectious Diseases</i> , 2019, 6, S34-S46.	0.9	136
23	Antimicrobial Activities of Tigecycline and Other Broad-Spectrum Antimicrobials Tested against Serine Carbapenemase- and Metallo- β -Lactamase-Producing Enterobacteriaceae : Report from the SENTRY Antimicrobial Surveillance Program. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 570-573.	3.2	131
24	Antimicrobial activity of ceftolozane/tazobactam tested against <i>Pseudomonas aeruginosa</i> and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011–12). <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2713-2722.	3.0	130
25	Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Organisms Collected from U.S. Medical Centers in 2012. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1684-1692.	3.2	129
26	OXA-163, an OXA-48-Related Class D β -Lactamase with Extended Activity Toward Expanded-Spectrum Cephalosporins. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2546-2551.	3.2	128
27	Wild-Type MIC Distributions and Epidemiological Cutoff Values for Amphotericin B, Flucytosine, and Itraconazole and <i>Candida</i> spp. as Determined by CLSI Broth Microdilution. <i>Journal of Clinical Microbiology</i> , 2012, 50, 2040-2046.	3.9	128
28	Variations in the Occurrence of Resistance Phenotypes and Carbapenemase Genes Among Enterobacteriaceae Isolates in 20 Years of the SENTRY Antimicrobial Surveillance Program. <i>Open Forum Infectious Diseases</i> , 2019, 6, S23-S33.	0.9	124
29	Effect of the β -Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5454-5458.	3.2	121
30	Detection of Methyltransferases Conferring High-Level Resistance to Aminoglycosides in Enterobacteriaceae from Europe, North America, and Latin America. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1843-1845.	3.2	119
31	Nosocomial Candidiasis: Antifungal Stewardship and the Importance of Rapid Diagnosis. <i>Medical Mycology</i> , 2016, 54, myv076.	0.7	119
32	Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013). <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 85, 200-204.	1.8	119
33	Mutation-Driven β -Lactam Resistance Mechanisms among Contemporary Ceftazidime-Nonsusceptible <i>Pseudomonas aeruginosa</i> Isolates from U.S. Hospitals. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6844-6850.	3.2	118
34	Low Prevalence of <i>fkp1</i> Hot Spot 1 Mutations in a Worldwide Collection of <i>Candida</i> Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2655-2659.	3.2	112
35	Ceftazidime-Avibactam Activity Tested against Enterobacteriaceae Isolates from U.S. Hospitals (2011 to) <i>Tj ETQq1 1 0.784314 rgBT /Ov</i> 2015, 59, 3509-3517.	3.2	104
36	Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 82, 303-313.	1.8	103

#	ARTICLE	IF	CITATIONS
37	Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant <i>Klebsiella pneumoniae</i> and <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	103
38	Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011). <i>Brazilian Journal of Infectious Diseases</i> , 2013, 17, 672-681.	0.6	101
39	Prevalence of β -Lactamase-Encoding Genes among Enterobacteriaceae Bacteremia Isolates Collected in 26 U.S. Hospitals: Report from the SENTRY Antimicrobial Surveillance Program (2010). <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3012-3020.	3.2	100
40	Detection of <i>mcr-1</i> among <i>Escherichia coli</i> Clinical Isolates Collected Worldwide as Part of the SENTRY Antimicrobial Surveillance Program in 2014 and 2015. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5623-5624.	3.2	100
41	Echinocandin and triazole antifungal susceptibility profiles for <i>Candida</i> spp., <i>Cryptococcus neoformans</i> , and <i>Aspergillus fumigatus</i> : application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 69, 45-50.	1.8	96
42	Dissemination and diversity of metallo- β -lactamases in Latin America: report from the SENTRY Antimicrobial Surveillance Program. <i>International Journal of Antimicrobial Agents</i> , 2005, 25, 57-61.	2.5	93
43	Comparison of <i>Escherichia coli</i> ST131 Pulsotypes, by Epidemiologic Traits, 1967–2009. <i>Emerging Infectious Diseases</i> , 2012, 18, 598-607.	4.3	93
44	First Descriptions of <i>bla</i> KPC in <i>Raoultella</i> spp. (<i>R. planticola</i> and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 <i>Clinical Microbiology</i> , 2009, 47, 4129-4130.	3.9	92
45	<i>Pseudomonas aeruginosa</i> Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	91
46	Occurrence and molecular characterization of fusidic acid resistance mechanisms among <i>Staphylococcus</i> spp. from European countries (2008). <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1353-1358.	3.0	89
47	Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> Isolates from U.S. Medical Centers, 2013 to 2016. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	89
48	Antimicrobial Susceptibility of Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015–2016. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 92, 69-74.	1.8	89
49	<i>Candida guilliermondii</i> and Other Species of <i>Candida</i> Misidentified as <i>Candida famata</i> : Assessment by Vitek 2, DNA Sequencing Analysis, and Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry in Two Global Antifungal Surveillance Programs. <i>Journal of Clinical Microbiology</i> , 2013, 51, 117-124.	3.9	88
50	Activity of MK-3118, a new oral glucan synthase inhibitor, tested against <i>Candida</i> spp. by two international methods (CLSI and EUCAST). <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 858-863.	3.0	87
51	Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in <i>Candida albicans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	87
52	Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against <i>Candida</i> and <i>Aspergillus</i> spp., including echinocandin- and azole-resistant isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2868-2873.	3.0	85
53	Activities of E1210 and Comparator Agents Tested by CLSI and EUCAST Broth Microdilution Methods against <i>Fusarium</i> and <i>Scedosporium</i> Species Identified Using Molecular Methods. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 352-357.	3.2	82
54	Regional data analysis of <i>Candida non-albicans</i> strains collected in United States medical sites over a 6-year period, 2006–2011. <i>Mycoses</i> , 2014, 57, 602-611.	4.0	82

#	ARTICLE	IF	CITATIONS
55	WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β -lactamases. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1696-1703.	3.0	81
56	United States resistance surveillance results for linezolid (LEADER Program for 2007). <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 62, 416-426.	1.8	80
57	<i>In Vitro</i> Activity of a New Oral Glucan Synthase Inhibitor (MK-3118) Tested against <i>Aspergillus</i> spp. by CLSI and EUCAST Broth Microdilution Methods. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1065-1068.	3.2	80
58	Rapid Emergence of β -CTX-M Among Enterobacteriaceae in U.S. Medical Centers: Molecular Evaluation from the MYSTIC Program (2007). <i>Microbial Drug Resistance</i> , 2008, 14, 211-216.	2.0	79
59	Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Ceftolozane in an <i>In Vitro</i> Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2809-2814.	3.2	79
60	Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15). <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1386-1395.	3.0	79
61	The Pandemic H30 Subclone of Sequence Type 131 (ST131) as the Leading Cause of Multidrug-Resistant <i>Escherichia coli</i> Infections in the United States (2011-2012). <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx089.	0.9	79
62	<i>In Vitro</i> Activity of Ceftaroline Against Multidrug-Resistant <i>Staphylococcus aureus</i> and <i>Streptococcus pneumoniae</i> : A Review of Published Studies and the AWARE Surveillance Program (2008-2010). <i>Clinical Infectious Diseases</i> , 2012, 55, S206-S214.	5.8	78
63	Resistance surveillance program report for selected European nations (2011). <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 78, 429-436.	1.8	78
64	Fusidic Acid Resistance Rates and Prevalence of Resistance Mechanisms among <i>Staphylococcus</i> spp. Isolated in North America and Australia, 2007-2008. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3614-3617.	3.2	77
65	<i>In vitro</i> activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 144-150.	2.5	77
66	<i>In Vitro</i> Activities of Isavuconazole and Comparator Antifungal Agents Tested against a Global Collection of Opportunistic Yeasts and Molds. <i>Journal of Clinical Microbiology</i> , 2013, 51, 2608-2616.	3.9	75
67	Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. <i>International Journal of Antimicrobial Agents</i> , 2015, 46, 53-59.	2.5	75
68	Regional Resistance Surveillance Program Results for 12 Asia-Pacific Nations (2011). <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5721-5726.	3.2	74
69	Ceftazidime-Avibactam Activity against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Isolated in U.S. Medical Centers in 2012 and 2013. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3656-3659.	3.2	74
70	Ceftolozane-Tazobactam Activity against <i>Pseudomonas aeruginosa</i> Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	73
71	Significance of Molecular Identification and Antifungal Susceptibility of Clinically Significant Yeasts and Moulds in a Global Antifungal Surveillance Programme. <i>Mycopathologia</i> , 2012, 174, 259-271.	3.1	72
72	Evolving oxazolidinone resistance mechanisms in a worldwide collection of enterococcal clinical isolates: results from the SENTRY Antimicrobial Surveillance Program. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2314-2322.	3.0	72

#	ARTICLE	IF	CITATIONS
73	Longitudinal (2001–14) analysis of enterococci and VRE causing invasive infections in European and US hospitals, including a contemporary (2010–13) analysis of oritavancin <i>in vitro</i> potency. Journal of Antimicrobial Chemotherapy, 2016, 71, 3453-3458.	3.0	71
74	Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-Resistant <i>Klebsiella pneumoniae</i> Bacteremia and Abscess in a Liver Transplant Recipient. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	71
75	Activity of Ceftaroline-Avibactam Tested against Gram-Negative Organism Populations, including Strains Expressing One or More β -Lactamases and Methicillin-Resistant <i>Staphylococcus aureus</i> Carrying Various Staphylococcal Cassette Chromosome <i>mec</i> Types. Antimicrobial Agents and Chemotherapy, 2012, 56, 4779-4785.	3.2	70
76	Update on Acinetobacter Species: Mechanisms of Antimicrobial Resistance and Contemporary In Vitro Activity of Minocycline and Other Treatment Options. Clinical Infectious Diseases, 2014, 59, S367-S373.	5.8	69
77	Carbapenem Resistance among <i>Pseudomonas aeruginosa</i> Strains from India: Evidence for Nationwide Endemicity of Multiple Metallo- β -Lactamase Clones (VIM-2, -5, -6, and -11 and the Newly) Tj ETQq1 1 03784314 rgBT /Overdo	3.2	68
78	Frequency of <i>fls</i> Mutations among <i>Candida glabrata</i> Isolates from a 10-Year Global Collection of Bloodstream Infection Isolates. Antimicrobial Agents and Chemotherapy, 2014, 58, 577-580.	3.2	67
79	<i>In Vitro</i> Activity of Plazomicin against Gram-Negative and Gram-Positive Isolates Collected from U.S. Hospitals and Comparative Activities of Aminoglycosides against Carbapenem-Resistant Enterobacteriaceae and Isolates Carrying Carbapenemase Genes. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	67
80	<i>In Vitro</i> Activity of a Novel Broad-Spectrum Antifungal, E1210, Tested against <i>Aspergillus</i> spp. Determined by CLSI and EUCAST Broth Microdilution Methods. Antimicrobial Agents and Chemotherapy, 2011, 55, 5155-5158.	3.2	66
81	Pharmacodynamics of β -Lactamase Inhibition by NXL104 in Combination with Ceftaroline: Examining Organisms with Multiple Types of β -Lactamases. Antimicrobial Agents and Chemotherapy, 2012, 56, 258-270.	3.2	66
82	Characterization of Global Patterns and the Genetics of Fusidic Acid Resistance. Clinical Infectious Diseases, 2011, 52, S487-S492.	5.8	65
83	Trends in carbapenemase-producing <i>Escherichia coli</i> and <i>Klebsiella</i> spp. from Europe and the Americas: report from the SENTRY antimicrobial surveillance programme (2007–09). Journal of Antimicrobial Chemotherapy, 2011, 66, 1409-1411.	3.0	65
84	Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of <i>Candida</i> Species. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	65
85	Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections. International Journal of Antimicrobial Agents, 2014, 44, 320-326.	2.5	64
86	Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 Systemically active antifungal agents when tested against <i>Candida</i> spp.. Diagnostic Microbiology and Infectious Disease, 2014, 79, 198-204.	1.8	64
87	Antimicrobial activities of doripenem and other carbapenems against <i>Pseudomonas aeruginosa</i> , other nonfermentative bacilli, and <i>Aeromonas</i> spp.. Diagnostic Microbiology and Infectious Disease, 2009, 63, 426-433.	1.8	63
88	WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	63
89	Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	61
90	Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant <i>Candida parapsilosis</i> and <i>Candida tropicalis</i> and country-specific isolate dissemination. International Journal of Antimicrobial Agents, 2020, 55, 105799.	2.5	61

#	ARTICLE	IF	CITATIONS
91	Characterization of an Integron Carrying bla IMP-1 and a New Aminoglycoside Resistance Gene, aac(6â€²)-31 , and Its Dissemination among Genetically Unrelated Clinical Isolates in a Brazilian Hospital. Antimicrobial Agents and Chemotherapy, 2007, 51, 2611-2614.	3.2	60
92	Triazole and Echinocandin MIC Distributions with Epidemiological Cutoff Values for Differentiation of Wild-Type Strains from Non-Wild-Type Strains of Six Uncommon Species of <i>Candida</i>. Journal of Clinical Microbiology, 2011, 49, 3800-3804.	3.9	59
93	Use of Micafungin as a Surrogate Marker To Predict Susceptibility and Resistance to Caspofungin among 3,764 Clinical Isolates of Candida by Use of CLSI Methods and Interpretive Criteria. Journal of Clinical Microbiology, 2014, 52, 108-114.	3.9	59
94	In vitro activity of a Hos2 deacetylase inhibitor, MGCD290, in combination with echinocandins against echinocandin-resistant Candida species. Diagnostic Microbiology and Infectious Disease, 2015, 81, 259-263.	1.8	59
95	How to: EUCAST recommendations on the screening procedure E.Def 10.1 for the detection of azole resistance in Aspergillus fumigatus isolates using four-well azole-containing agar plates. Clinical Microbiology and Infection, 2019, 25, 681-687.	6.0	59
96	Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010â€“2013). Diagnostic Microbiology and Infectious Disease, 2015, 83, 183-186.	1.8	58
97	First Report of <i>bla</i>-sub>VIM-4</sub> - and <i>mcr-9</i> -Coharboring <i>Enterobacter</i> Species Isolated from a Pediatric Patient. MSphere, 2019, 4, .	2.9	58
98	Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method. Diagnostic Microbiology and Infectious Disease, 2011, 71, 252-259.	1.8	56
99	ZAAPS programme results for 2016: an activity and spectrum analysis of linezolid using clinical isolates from medical centres in 42 countries. Journal of Antimicrobial Chemotherapy, 2018, 73, 1880-1887.	3.0	56
100	High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-Î²-lactamase Production in <i>Enterobacteriaceae</i> Bloodstream Infections at a Major Cancer Center: Table 1.. Clinical Infectious Diseases, 2016, 63, 954-958.	5.8	55
101	CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program. International Journal of Antimicrobial Agents, 2017, 50, 352-358.	2.5	55
102	Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015â€“17). Journal of Antimicrobial Chemotherapy, 2018, 73, 3053-3059.	3.0	55
103	Rapid Expansion of KPC-2-Producing <i>Klebsiella pneumoniae</i> Isolates in Two Texas Hospitals due to Clonal Spread of ST258 and ST307 Lineages. Microbial Drug Resistance, 2013, 19, 295-297.	2.0	54
104	In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution method. Diagnostic Microbiology and Infectious Disease, 2011, 71, 167-170.	1.8	53
105	Evaluation of Clonality and Carbapenem Resistance Mechanisms among Acinetobacter baumannii-Acinetobacter calcoaceticus Complex and Enterobacteriaceae Isolates Collected in European and Mediterranean Countries and Detection of Two Novel Î²-Lactamases, GES-22 and VIM-35. Antimicrobial Agents and Chemotherapy, 2014, 58, 7358-7366.	3.2	53
106	Changes in the Frequencies of Î²-Lactamase Genes among Enterobacteriaceae Isolates in U.S. Hospitals, 2012 to 2014: Activity of Ceftazidime-Avibactam Tested against Î²-Lactamase-Producing Isolates. Antimicrobial Agents and Chemotherapy, 2016, 60, 4770-4777.	3.2	53
107	Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: results from SENTRY Antimicrobial Surveillance Program (2011â€“2014). International Journal of Antimicrobial Agents, 2016, 48, 144-150.	2.5	52
108	Trends in Klebsiella pneumoniae carbapenemase-positive K. pneumoniae in US hospitals: report from the 2007â€“2009 SENTRY Antimicrobial Surveillance Program. Diagnostic Microbiology and Infectious Disease, 2013, 76, 356-360.	1.8	50

#	ARTICLE	IF	CITATIONS
109	Antifungal susceptibilities of <i>Candida</i> , <i>Cryptococcus neoformans</i> and <i>Aspergillus fumigatus</i> from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010–2012). <i>Journal of Antibiotics</i> , 2015, 68, 556-561.	2.0	50
110	Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	50
111	Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3346-3354.	3.0	50
112	Murepavadin activity tested against contemporary (2016–17) clinical isolates of XDR <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2400-2404.	3.0	50
113	Geographical and temporal variation in the frequency and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bacterial pneumonia: results from 20 years of the SENTRY Antimicrobial Surveillance Program (1997–2016). <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1595-1606.	3.0	49
114	CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria. <i>Diagnostic Microbiology and Infectious Disease</i> , 2010, 66, 393-401.	1.8	48
115	Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against <i>Enterobacteriaceae</i> and <i>Pseudomonas aeruginosa</i> with Various Resistance Patterns Isolated in U.S. Hospitals (2013–2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility. <i>Microbial Drug Resistance</i> , 2018, 24, 563-577.	2.0	48
116	Low Frequency of Ceftazidime-Avibactam Resistance among Enterobacteriaceae Isolates Carrying <i>bla</i> -KPC Collected in U.S. Hospitals from 2012 to 2015. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	47
117	Emergence of the Extended-Spectrum β -Lactamase GES-1 in a <i>Pseudomonas aeruginosa</i> Strain from Brazil: Report from the SENTRY Antimicrobial Surveillance Program. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 2344-2345.	3.2	46
118	Increasing carbapenem resistance due to the clonal dissemination of oxacillinase (OXA-23 and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 38 of <i>Medical Microbiology</i> , 2008, 57, 1529-1532.	1.8	46
119	Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus <i>Candida</i> : comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methods. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2581-2584.	3.0	46
120	Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011–2016). <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 608-611.	2.5	46
121	Activity of Ceftolozane-Tazobactam against <i>Pseudomonas aeruginosa</i> and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	46
122	First Isolation of <i>bla</i> VIM-2 in Latin America: Report from the SENTRY Antimicrobial Surveillance Program. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 1433-1434.	3.2	45
123	Antimicrobial Susceptibility Patterns of KPC-Producing or CTX-M-Producing Enterobacteriaceae. <i>Microbial Drug Resistance</i> , 2010, 16, 61-65.	2.0	45
124	Epidemic Emergence in the United States of <i>Escherichia coli</i> Sequence Type 131- <i>H</i> 30 (ST131-) Tj ETQq0 0 0 rgBT /Overlock 10 T	3.2	45
125	Application of Next-Generation Sequencing for Characterization of Surveillance and Clinical Trial Isolates: Analysis of the Distribution of β -lactamase Resistance Genes and Lineage Background in the United States. <i>Open Forum Infectious Diseases</i> , 2019, 6, S69-S78.	0.9	45
126	Use of Anidulafungin as a Surrogate Marker To Predict Susceptibility and Resistance to Caspofungin among 4,290 Clinical Isolates of <i>Candida</i> by Using CLSI Methods and Interpretive Criteria. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3223-3229.	3.9	44

#	ARTICLE	IF	CITATIONS
127	Meropenem-Vaborbactam Activity against Carbapenem-Resistant <i>Enterobacterales</i> Isolates Collected in U.S. Hospitals during 2016 to 2018. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	44
128	Antimicrobial characterisation of CEM-101 activity against respiratory tract pathogens, including multidrug-resistant pneumococcal serogroup 19A isolates. <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 537-543.	2.5	43
129	Candidemia surveillance in Iowa: emergence of echinocandin resistance. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 79, 205-208.	1.8	43
130	<i>In Vitro</i> Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	43
131	Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006). <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 61, 235-239.	1.8	42
132	Isavuconazole and Nine Comparator Antifungal Susceptibility Profiles for Common and Uncommon <i>Candida</i> Species Collected in 2012: Application of New CLSI Clinical Breakpoints and Epidemiological Cutoff Values. <i>Mycopathologia</i> , 2014, 178, 1-9.	3.1	42
133	Analysis of <i>Candida auris</i> fungemia at a single facility in Kenya. <i>International Journal of Infectious Diseases</i> , 2019, 85, 182-187.	3.3	42
134	Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018). <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	42
135	Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an <i>In Vitro</i> Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2075-2080.	3.2	40
136	Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	40
137	Expansion of Clonal Complex 258 KPC-2-Producing <i>Klebsiella pneumoniae</i> in Latin American Hospitals: Report of the SENTRY Antimicrobial Surveillance Program. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1668-1669.	3.2	39
138	Relationship between Ceftolozane-Tazobactam Exposure and Selection for <i>Pseudomonas aeruginosa</i> Resistance in a Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6024-6031.	3.2	39
139	Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015-2017) isolates from hospitalized patients with pneumonia in US medical centers. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 94, 93-102.	1.8	39
140	In Vitro Antimicrobial Findings for Fusidic Acid Tested Against Contemporary (2008-2009) Gram-Positive Organisms Collected in the United States. <i>Clinical Infectious Diseases</i> , 2011, 52, S477-S486.	5.8	38
141	Optimizing Echinocandin Dosing and Susceptibility Breakpoint Determination via <i>In Vivo</i> Pharmacodynamic Evaluation against <i>Candida glabrata</i> with and without <i>FKS</i> Mutations. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5875-5882.	3.2	38
142	Relationship between Ceftolozane-Tazobactam Exposure and Drug Resistance Amplification in a Hollow-Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4134-4138.	3.2	38
143	First Report of Plasmid-Mediated qnrA1 in a Ciprofloxacin-Resistant <i>Escherichia coli</i> Strain in Latin America. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1527-1529.	3.2	37
144	TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 716-720.	3.0	37

#	ARTICLE	IF	CITATIONS
145	CEM-101 Activity against Gram-Positive Organisms. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2182-2187.	3.2	37
146	Antimicrobial Susceptibility of <i>Pseudomonas aeruginosa</i> to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	37
147	Comparative Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Enterobacteriaceae Isolates Producing Extended-Spectrum β -Lactamases from U.S. Hospitals. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	37
148	Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci. <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 39-45.	2.5	36
149	Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 659-666.	3.0	36
150	Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals. <i>International Journal of Antimicrobial Agents</i> , 2021, 58, 106439.	2.5	36
151	Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013â€“2015). <i>Brazilian Journal of Infectious Diseases</i> , 2017, 21, 627-637.	0.6	35
152	Antimicrobial activity of ceftobiprole and comparator agents when tested against contemporary Gram-positive and -negative organisms collected from Europe (2015). <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 91, 77-84.	1.8	35
153	<i>In vitro</i> antifungal susceptibilities of isolates of <i>Candida</i> spp. and <i>Aspergillus</i> spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012. <i>Mycoses</i> , 2015, 58, 209-214.	4.0	34
154	Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime/avibactam resistance in <i>Pseudomonas aeruginosa</i> clinical isolates from US hospitals. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2588-2595.	3.0	34
155	<i>In Vitro</i> Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program. <i>Microbiology Spectrum</i> , 2022, 10, e0271221.	3.0	34
156	The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009). <i>Journal of Infection</i> , 2010, 61, 476-483.	3.3	33
157	Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3125-3134.	3.0	33
158	First Description of blaCTX-M-14- and blaCTX-M-15-Producing <i>Escherichia coli</i> isolates in Brazil. <i>Microbial Drug Resistance</i> , 2010, 16, 177-184.	2.0	32
159	Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> collected from patients with bloodstream infections isolated in United States hospitals (2013â€“2015) as part of the Program to Assess Ceftolozane-Tazobactam Susceptibility (PACTS) surveillance program. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 92, 158-163.	1.8	32
160	Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017â€“2018). <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 96, 114833.	1.8	32
161	Molecular typing of antimicrobial-resistant Shiga-toxin-producing <i>Escherichia coli</i> strains (STEC) in Brazil. <i>Research in Microbiology</i> , 2011, 162, 117-123.	2.1	31
162	Molecular β -Lactamase Characterization of Aerobic Gram-Negative Pathogens Recovered from Patients Enrolled in the Ceftazidime-Avibactam Phase 3 Trials for Complicated Intra-abdominal Infections, with Efficacies Analyzed against Susceptible and Resistant Subsets. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	31

#	ARTICLE	IF	CITATIONS
163	Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia) Tj ETQq1 1 0,784314 rgBT /Overle	2.5	31
164	<i>In Vitro</i> Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014. Antimicrobial Agents and Chemotherapy, 2016, 60, 2537-2541.	3.2	30
165	<i>In Vitro</i> Activity of Minocycline against U.S. Isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus Species Complex, Stenotrophomonas maltophilia, and Burkholderia cepacia Complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	30
166	Aminoglycoside-modifying enzyme and 16S ribosomal RNA methyltransferase genes among a global collection of Gram-negative isolates. Journal of Global Antimicrobial Resistance, 2019, 16, 278-285.	2.2	30
167	Kinetic Characterization of VIM-7, a Divergent Member of the VIM Metallo-Î²-Lactamase Family. Antimicrobial Agents and Chemotherapy, 2008, 52, 2905-2908.	3.2	29
168	Potency of Anidulafungin Compared to Nine Other Antifungal Agents Tested against <i>Candida</i> spp., <i>Cryptococcus</i> spp., and <i>Aspergillus</i> spp.: Results from the Global SENTRY Antimicrobial Surveillance Program (2008). Journal of Clinical Microbiology, 2010, 48, 2984-2987.	3.9	29
169	Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada. International Journal of Antimicrobial Agents, 2010, 35, 282-287.	2.5	29
170	<i>In Vitro</i> Antibacterial Activity of Cefiderocol against Multidrug-Resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2021, 65, e0264620.	3.2	29
171	Minocycline activity tested against Acinetobacter baumannii complex, Stenotrophomonas maltophilia , and Burkholderia cepacia species complex isolates from a global surveillance program (2013). Diagnostic Microbiology and Infectious Disease, 2016, 85, 352-355.	1.8	28
172	Distribution of main Gram-positive pathogens causing bloodstream infections in United States and European hospitals during the SENTRY Antimicrobial Surveillance Program (2010â€“2016): concomitant analysis of oritavancin <i>in vitro</i> activity. Journal of Chemotherapy, 2018, 30, 280-289.	1.5	28
173	Analyses of a Ceftazidime-Avibactam-Resistant <i>Citrobacter freundii</i> Isolate Carrying <i>bla</i> _{KPC-2} Reveals a Heterogenous Population and Reversible Genotype. MSphere, 2018, 3, .	2.9	28
174	Isolation of Genetically Unrelated <i>bla</i> _{NDM-1} -Positive Providencia rettgeri Strains in Israel. Journal of Clinical Microbiology, 2013, 51, 1642-1643.	3.9	27
175	Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications. Journal of Antimicrobial Chemotherapy, 2022, 77, 2053-2073.	3.0	27
176	<i>Candida glabrata</i> Mutants Demonstrating Paradoxical Reduced Caspofungin Susceptibility but Increased Micafungin Susceptibility. Antimicrobial Agents and Chemotherapy, 2011, 55, 3947-3949.	3.2	26
177	Update of contemporary antimicrobial resistance rates across China: reference testing results for 12 medical centers (2011). Diagnostic Microbiology and Infectious Disease, 2013, 77, 258-266.	1.8	26
178	Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Gram-Negative Organisms Isolated from Patients with Urinary Tract Infections in U.S. Medical Centers, 2012 to 2014. Antimicrobial Agents and Chemotherapy, 2016, 60, 4355-4360.	3.2	26
179	Molecular Î²-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets. International Journal of Antimicrobial Agents, 2018, 52, 287-292.	2.5	26
180	Bacterial and fungal pathogens isolated from patients with bloodstream infection: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (2012â€“2017). Diagnostic Microbiology and Infectious Disease, 2020, 97, 115016.	1.8	26

#	ARTICLE	IF	CITATIONS
181	Evaluation of Synergistic Activity of Isavuconazole or Voriconazole plus Anidulafungin and the Occurrence and Genetic Characterization of <i>Candida auris</i> Detected in a Surveillance Program. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	26
182	Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible <i>Citrobacter</i> spp., <i>Enterobacter</i> spp., <i>Serratia marcescens</i> , and <i>Pseudomonas aeruginosa</i> from United States medical centers (2011–2014). <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 83, 389-394.	1.8	25
183	Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018–2019). <i>Journal of Global Antimicrobial Resistance</i> , 2021, 26, 117-127.	2.2	25
184	β -Lactamase Characterization of Gram-Negative Pathogens Recovered from Patients Enrolled in the Phase 2 Trials for Ceftazidime-Avibactam: Clinical Efficacies Analyzed against Subsets of Molecularly Characterized Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1328-1335.	3.2	24
185	Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	24
186	Antimicrobial activity of cefoperazone-sulbactam tested against Gram-Negative organisms from Europe, Asia-Pacific, and Latin America. <i>International Journal of Infectious Diseases</i> , 2020, 91, 32-37.	3.3	24
187	Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant <i>Escherichia coli</i> Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	24
188	Dissemination of blaIMP-1-carrying integron In86 among <i>Klebsiella pneumoniae</i> isolates harboring a new trimethoprim resistance gene dfr23. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 63, 87-91.	1.8	23
189	Mechanisms of Resistance, Clonal Expansion, and Increasing Prevalence of <i>Acinetobacter baumannii</i> Strains Displaying Elevated Tigecycline MIC Values in Latin America. <i>Microbial Drug Resistance</i> , 2016, 22, 253-258.	2.0	23
190	Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in U.S. Hospitals during 2014 to 2018. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	23
191	Activity of Fusidic Acid Tested against Staphylococci Isolated from Patients in U.S. Medical Centers in 2014. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3827-3831.	3.2	22
192	Multidrug-resistant <i>Pseudomonas aeruginosa</i> from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime–avibactam. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 1499-1510.	2.7	22
193	Carriage of methicillin-resistant <i>Staphylococcus aureus</i> in children in Brazil. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 57, 467-470.	1.8	21
194	Update on the prevalence and genetic characterization of NDM-1–producing Enterobacteriaceae in Indian hospitals during 2010. <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 75, 210-213.	1.8	21
195	Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from patients hospitalized with bloodstream infections in United States medical centers (2015–2017). <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 95, 114850.	1.8	21
196	Characterization of β -Lactamase Content of Ceftazidime-Resistant Pathogens Recovered during the Pathogen-Directed Phase 3 REPRISE Trial for Ceftazidime-Avibactam: Correlation of Efficacy against β -Lactamase Producers. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	21
197	Activity of meropenem/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014–19). <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2600-2605.	3.0	21
198	Antimicrobial susceptibility of Gram-negative bacteria from intensive care unit and non-intensive care unit patients from United States hospitals (2018–2020). <i>Diagnostic Microbiology and Infectious Disease</i> , 2022, 102, 115557.	1.8	21

#	ARTICLE	IF	CITATIONS
199	Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011â€“13): Table 1.. Journal of Antimicrobial Chemotherapy, 2016, 71, 276-278.	3.0	20
200	Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010â€“2014. Diagnostic Microbiology and Infectious Disease, 2018, 91, 199-204.	1.8	20
201	Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and Î²-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values. International Journal of Antimicrobial Agents, 2020, 56, 106011.	2.5	20
202	Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against <i>Pseudomonas aeruginosa</i> and <i>Klebsiella pneumoniae</i> Isolates from United States Medical Centers in 2016â€“2018. Microbial Drug Resistance, 2021, 27, 342-349.	2.0	20
203	RmtD 16S RNA Methylase in Epidemiologically Unrelated SPM-1-Producing <i>Pseudomonas aeruginosa</i> Isolates from Brazil. Antimicrobial Agents and Chemotherapy, 2008, 52, 1587-1588.	3.2	19
204	Dissemination of a blaVIM-2-Carrying Integron Among Enterobacteriaceae Species in Mexico: Report from the SENTRY Antimicrobial Surveillance Program. Microbial Drug Resistance, 2009, 15, 33-35.	2.0	19
205	Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals. Pediatric Infectious Disease Journal, 2017, 36, 486-491.	2.0	19
206	Activity of tedizolid against gram-positive clinical isolates causing infections in Europe and surrounding areas (2014â€“2015). Journal of Chemotherapy, 2019, 31, 188-194.	1.5	18
207	First reported human isolation of Staphylococcus delphini. Diagnostic Microbiology and Infectious Disease, 2019, 94, 274-276.	1.8	17
208	Antimicrobial activity of ceftazidime/avibactam, ceftolozane/tazobactam and comparator agents against <i>Pseudomonas aeruginosa</i> from cystic fibrosis patients. JAC-Antimicrobial Resistance, 2021, 3, dlab126.	2.1	17
209	Emergence and Clonal Dissemination of OXA-24- and OXA-58-Producing Acinetobacter baumannii Strains in Houston, Texas: Report from the SENTRY Antimicrobial Surveillance Program. Journal of Clinical Microbiology, 2008, 46, 3179-3180.	3.9	16
210	Codetection of <i>bla</i> _{OXA-23} -Like Gene (<i>bla</i> _{OXA-133}) and <i>bla</i> _{OXA-58} in <i>Acinetobacter radioresistens</i> : Report from the SENTRY Antimicrobial Surveillance Program. Antimicrobial Agents and Chemotherapy, 2009, 53, 843-844.	3.2	16
211	Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013. Diagnostic Microbiology and Infectious Disease, 2015, 82, 78-84.	1.8	16
212	In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011â€“2013). International Journal of Antimicrobial Agents, 2016, 47, 495-499.	2.5	16
213	Updated Prevalence of <i>mcr</i> -Like Genes among <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> in the SENTRY Program and Characterization of <i>mcr</i> -1.11 Variant. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	16
214	In vitro activity of Plazomicin against Enterobacteriaceae isolates carrying genes encoding aminoglycoside-modifying enzymes most common in US Census divisions. Diagnostic Microbiology and Infectious Disease, 2019, 94, 73-77.	1.8	16
215	<i>In Vitro</i> Activity of the Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Multiple Beta-Lactam Antibiotics against Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	16
216	Metallo-beta-lactamases. Jornal Brasileiro De Patologia E Medicina Laboratorial, 2006, 42, 103-113.	0.3	15

#	ARTICLE	IF	CITATIONS
217	Clonal Dissemination of <i>Klebsiella pneumoniae</i> Carbapenemase KPC-3 in Long Beach, California. <i>Journal of Clinical Microbiology</i> , 2010, 48, 623-625.	3.9	15
218	Evaluation of quinolone resistance—determining region mutations and efflux pump expression in <i>Neisseria meningitidis</i> resistant to fluoroquinolones. <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 72, 263-266.	1.8	15
219	Activity of Ceftaroline-Avibactam Tested Against Contemporary Enterobacteriaceae Isolates Carrying β -Lactamases Prevalent in the United States. <i>Microbial Drug Resistance</i> , 2014, 20, 436-440.	2.0	15
220	<i>Klebsiella pneumoniae</i> Isolate from a New York City Hospital Belonging to Sequence Type 258 and Carrying blaKPC-2 and blaVIM-4. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1924-1927.	3.2	15
221	Frequency and antimicrobial susceptibility of bacteria causing bloodstream infections in pediatric patients from United States (US) medical centers (2014–2018): therapeutic options for multidrug-resistant bacteria. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 98, 115108.	1.8	15
222	Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against <i>Pseudomonas aeruginosa</i> from patients with skin and soft tissue infections. <i>International Journal of Infectious Diseases</i> , 2021, 113, 279-281.	3.3	15
223	Fungemia Surveillance in Denmark Demonstrates Emergence of Non-albicans <i>Candida</i> Species and Higher Antifungal Usage and Resistance Rates than in Other Nations. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	14
224	Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary <i>Stenotrophomonas maltophilia</i> Isolates from Medical Centers Worldwide. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	14
225	Evaluating the emergence of nonsusceptibility among <i>Pseudomonas aeruginosa</i> respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP). <i>International Journal of Antimicrobial Agents</i> , 2021, 57, 106278.	2.5	14
226	Global molecular epidemiology of carbapenem-resistant <i>Escherichia coli</i> (2002–2017). <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, , 1.	2.9	14
227	Activity of Plazomicin Tested against <i>Enterobacterales</i> Isolates Collected from U.S. Hospitals in 2016–2017: Effect of Different Breakpoint Criteria on Susceptibility Rates among Aminoglycosides. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	14
228	Performance of Fusidic Acid (CEM-102) Susceptibility Testing Reagents: Broth Microdilution, Disk Diffusion, and Etest Methods as Applied to <i>Staphylococcus aureus</i> . <i>Journal of Clinical Microbiology</i> , 2010, 48, 972-976.	3.9	13
229	Ceftazidime-Avibactam Activity against Aerobic Gram Negative Organisms Isolated from Intra-Abdominal Infections in United States Hospitals, 2012–2014. <i>Surgical Infections</i> , 2016, 17, 473-478.	1.4	13
230	Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in North American, Latin American, European and Asia-Pacific nations. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 88, 184-187.	1.8	13
231	Activity of Imipenem-Relebactam against Carbapenem-Resistant <i>Escherichia coli</i> Isolates from the United States in Relation to Clonal Background, Resistance Genes, Coresistance, and Region. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	13
232	In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY Antifungal Surveillance Program, 2017–2018. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 97, 115007.	1.8	13
233	Investigation of mechanisms responsible for decreased susceptibility of aztreonam/avibactam activity in clinical isolates of <i>Enterobacterales</i> collected in Europe, Asia and Latin America in 2019. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2833-2838.	3.0	13
234	Molecular Characterization of Baseline <i>Enterobacterales</i> and <i>Pseudomonas aeruginosa</i> Isolates from a Phase 3 Nosocomial Pneumonia (ASPECT-NP) Clinical Trial. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	13

#	ARTICLE	IF	CITATIONS
235	Impact of COVID-19 on the antifungal susceptibility profiles of isolates collected in a global surveillance program that monitors invasive fungal infections. <i>Medical Mycology</i> , 2022, 60, .	0.7	13
236	Azole resistance in <i>Candida glabrata</i> clinical isolates from global surveillance is associated with efflux overexpression. <i>Journal of Global Antimicrobial Resistance</i> , 2022, 29, 371-377.	2.2	13
237	Dissemination and genetic context analysis of blaVIM-6 among <i>Pseudomonas aeruginosa</i> isolates in Asian-Pacific Nations. <i>Clinical Microbiology and Infection</i> , 2010, 16, 186-189.	6.0	12
238	Comment on: Role of changes in the L3 loop of the active site in the evolution of enzymatic activity of VIM-type metallo- β -lactamases. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 684-685.	3.0	12
239	Activity of ceftaroline and comparator agents tested against contemporary Gram-positive and -negative (2011) isolates collected in Europe, Turkey, and Israel. <i>Journal of Chemotherapy</i> , 2014, 26, 202-210.	1.5	12
240	Enhanced activity of cefepime+tazobactam (WCK 4282) against KPC-producing Enterobacteriaceae when tested in media supplemented with human serum or sodium chloride. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 89, 305-309.	1.8	12
241	Comparative activity of newer β -lactam/ β -lactamase inhibitor combinations against <i>Pseudomonas aeruginosa</i> from patients hospitalized with pneumonia in European medical centers in 2020. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 319-324.	2.9	12
242	Antimicrobial activities of aztreonam-avibactam and comparator agents tested against Enterobacterales from European hospitals analysed by geographic region and infection type (2019-2020). <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 477-487.	2.9	12
243	IMP-15-Producing <i>Pseudomonas aeruginosa</i> Strain Isolated in a U.S. Medical Center: a Recent Arrival from Mexico. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2289-2290.	3.2	10
244	Determination of CEM-101 Activity Tested against Clinical Isolates of <i>Neisseria meningitidis</i> from a Worldwide Collection. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4009-4011.	3.2	10
245	Retrospective Molecular Analysis of DIM-1 Metallo- β -Lactamase Discovered in <i>Pseudomonas stutzeri</i> from India in 2000. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 596-598.	3.2	10
246	In Vitro Antifungal Susceptibility of <i>Candida glabrata</i> to Caspofungin and the Presence of FKS Mutations Correlate with Treatment Response in an Immunocompromised Murine Model of Invasive Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3646-3649.	3.2	10
247	In Vitro Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census Divisions. <i>Microbial Drug Resistance</i> , 2017, 23, 718-726.	2.0	10
248	Activity of meropenem/vaborbactam against international carbapenem-resistant <i>Escherichia coli</i> isolates in relation to clonal background, resistance genes, resistance to comparators and region. <i>Journal of Global Antimicrobial Resistance</i> , 2021, 24, 190-197.	2.2	10
249	Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2522-2531.	3.0	10
250	Changing Antimicrobial Susceptibility Patterns among <i>Streptococcus pneumoniae</i> and <i>Haemophilus influenzae</i> from Brazil: Report from the SENTRY Antimicrobial Surveillance Program (1998-2004). <i>Microbial Drug Resistance</i> , 2006, 12, 91-98.	2.0	9
251	Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015). <i>Journal of Global Antimicrobial Resistance</i> , 2017, 11, 4-7.	2.2	9
252	Antifungal susceptibilities of opportunistic filamentous fungal pathogens from the Asia and Western Pacific Region: data from the SENTRY Antifungal Surveillance Program (2011-2019). <i>Journal of Antibiotics</i> , 2021, 74, 519-527.	2.0	9

#	ARTICLE	IF	CITATIONS
253	Isavuconazole nonwildtype <i>Aspergillus fumigatus</i> isolates from a global surveillance study display alterations in multiple genes involved in the ergosterol biosynthesis pathway not previously associated with resistance to other azoles. <i>Mycoses</i> , 2021, 64, 1279-1290.	4.0	9
254	In vitro activity of posaconazole and comparators versus opportunistic filamentous fungal pathogens globally collected during 8 years. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 101, 115473.	1.8	9
255	Elderly versus nonelderly patients with invasive fungal infections: species distribution and antifungal resistance, SENTRY antifungal surveillance program 2017-2019. <i>Diagnostic Microbiology and Infectious Disease</i> , 2022, 102, 115627.	1.8	9
256	Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020). <i>Journal of Clinical Microbiology</i> , 2022, 60, e0244921.	3.9	9
257	In71, an <i>Enterobacter cloacae</i> bla _{VIM-1} -Carrying Integron Related to In70.2 from Italian <i>Pseudomonas aeruginosa</i> Isolates: A SENTRY Antimicrobial Surveillance Program Report. <i>Microbial Drug Resistance</i> , 2007, 13, 130-134.	2.0	8
258	<i>Candida glabrata</i> : Multidrug Resistance and Increased Virulence in a Major Opportunistic Fungal Pathogen. <i>Current Fungal Infection Reports</i> , 2012, 6, 154-164.	2.6	8
259	Prevalence of macrolide–lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents. <i>Journal of Global Antimicrobial Resistance</i> , 2017, 8, 28-32.	2.2	8
260	Determination of MIC and disk diffusion quality control guidelines for meropenem–vaborbactam, a novel carbapenem/boronic acid β -lactamase inhibitor combination. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 90, 324-328.	1.8	8
261	Postmarketing experience with Neutrolin® (taurolidine, heparin, calcium citrate) catheter lock solution in hemodialysis patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 661-663.	2.9	8
262	<i>Klebsiella pneumoniae</i> Carbapenemase-Producing Enterobacteriaceae Testing Susceptible to Cefepime by Reference Methods. <i>Journal of Clinical Microbiology</i> , 2013, 51, 2388-2390.	3.9	7
263	Frequency of occurrence and antimicrobial susceptibility of bacteria isolated from respiratory samples of patients hospitalized with pneumonia in Western Europe, Eastern Europe and the USA: results from the SENTRY Antimicrobial Surveillance Program (2016–19). <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab117.	2.1	7
264	Typing and Molecular Characterization of <i>Streptococcus pneumoniae</i> with Reduced Susceptibility to Cefotaxime Isolated in Latin America. <i>Microbial Drug Resistance</i> , 2003, 9, 345-351.	2.0	6
265	Ceftaroline activity tested against viridans group streptococci from US hospitals. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 84, 232-235.	1.8	6
266	Antimicrobial activity of ceftazidime–avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013–2014). <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 87, 261-265.	1.8	6
267	Case report of transient mcr-1 -harboring <i>Escherichia coli</i> with concurrent <i>Staphylococcus aureus</i> bacteremia in Long Beach, California. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017, 89, 303-304.	1.8	6
268	Analysis of Multidrug Resistance in <i>Staphylococcus aureus</i> with a Machine Learning-Generated Antibigram. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	6
269	In vitro activity of the orally bioavailable ceftibuten/VNRX-7145 (VNRX-5236 etzadroxil) combination against a challenge set of Enterobacterales pathogens carrying molecularly characterized β -lactamase genes. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 689-694.	3.0	6
270	Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010–2019). <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0166721.	3.2	6

#	ARTICLE	IF	CITATIONS
271	IMP-33, a New IMP Variant Detected in <i>Pseudomonas aeruginosa</i> from Sicily. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 6401-6403.	3.2	5
272	In Vitro Activity Analysis of a New Polymyxin, SPR741, Tested in Combination with Antimicrobial Agents against a Challenge Set of Enterobacteriaceae , Including Molecularly Characterized Strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	3.2	5
273	Comparative activity of posaconazole and systemic azole agents against clinical isolates of filamentous fungi from a global surveillance programme. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab088.	2.1	5
274	Activity of plazomicin against carbapenem-intermediate or -resistant <i>Escherichia coli</i> isolates from the United States and international sites in relation to clonal background, resistance genes, co-resistance, and region. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2061-2070.	3.0	5
275	Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018–2020). <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 867-873.	2.9	5
276	Definitions and Epidemiology of <i>Candida</i> Species not Susceptible to Echinocandins. <i>Current Fungal Infection Reports</i> , 2011, 5, 120-127.	2.6	4
277	Detection of NDM-1-producing Enterobacteriaceae in Romania: report of the SENTRY Antimicrobial Surveillance Program. <i>Journal of Medical Microbiology</i> , 2014, 63, 483-484.	1.8	4
278	Voriconazole minimum inhibitory concentrations are predictive of treatment outcome in experimental murine infections by <i>Candida glabrata</i> . <i>International Journal of Antimicrobial Agents</i> , 2016, 47, 286-288.	2.5	4
279	The application of in vitro surveillance data for antibacterial dose selection. <i>Current Opinion in Pharmacology</i> , 2017, 36, 130-138.	3.5	4
280	Media for colistin susceptibility testing does not improve the detection of <i>Klebsiella pneumoniae</i> isolates carrying <i>MgrB</i> disruption and other mutation driven colistin resistance mechanisms. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 98, 115077.	1.8	4
281	Activity of the Novel Aminomethylcycline KBP-7072 and Comparators against 1,057 Geographically Diverse Recent Clinical Isolates from the SENTRY Surveillance Program, 2019. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0139721.	3.2	4
282	Fixed-Ratio Combination Testing of an Echinocandin, Anidulafungin, and an Azole, Voriconazole, against 1,467 <i>Candida</i> Species Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4041-4043.	3.2	3
283	677. Activity of Novel β -Lactamase Inhibitor QPX7728 Combined with β -Lactam Agents When Tested Against Carbapenem-Resistant Enterobacteriaceae (CRE) Isolates. <i>Open Forum Infectious Diseases</i> , 2019, 6, S309-S309.	0.9	3
284	Omadacycline invitro activity against a molecularly characterized collection of clinical isolates with known acquired tetracycline resistance mechanisms. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 97, 115054.	1.8	3
285	Characterization of <i>Enterobacter cloacae</i> and <i>Citrobacter freundii</i> species complex isolates with decreased susceptibility to cephalosporins from United States hospitals and activity of ceftazidime/avibactam and comparator agents. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab136.	2.1	3
286	Minocycline Activity against Unusual Clinically Significant Gram-Negative Pathogens. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0126421.	3.2	3
287	Evaluation of the Post-antifungal Effect of Rezafungin and Micafungin against <i>Candida albicans</i> , <i>Candida parapsilosis</i> and <i>Candida glabrata</i> . <i>Mycoses</i> , 0, , .	4.0	3
288	Activity of JNJ-Q2 against <i>Staphylococcus aureus</i> isolated from patients with acute bacterial skin and skin-structure infection obtained during a Phase 2 clinical trial. <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 74, 73-74.	1.8	2

#	ARTICLE	IF	CITATIONS
289	Advances in Antifungal Susceptibility Testing of Candida, 2010â€“2012. Current Fungal Infection Reports, 2012, 6, 141-153.	2.6	2
290	Antimicrobial activity of oritavancin and comparator agents when tested against Gram-positive bacterial isolates causing infections in cancer patients (2014â€“16). Journal of Antimicrobial Chemotherapy, 2018, 73, 916-922.	3.0	2
291	Antimicrobial activity of high-dose cefepime-tazobactam (WCK 4282) against a large collection of gram-negative organisms collected worldwide in 2018 and 2019. International Journal of Infectious Diseases, 2022, 116, 306-312.	3.3	2
292	Selection of the appropriate avibactam concentration for use with ceftibuten in broth microdilution susceptibility testing. Diagnostic Microbiology and Infectious Disease, 2022, 103, 115673.	1.8	2
293	Direct in vitro comparison of the prodrug isavuconazonium sulfate with the isavuconazole active compound against Aspergillus spp. and 2 rare moulds. Diagnostic Microbiology and Infectious Disease, 2018, 92, 43-45.	1.8	1
294	2115. Activity of a Long-Acting Echinocandin Rezafungin and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates: SENTRY 2018. Open Forum Infectious Diseases, 2019, 6, S716-S716.	0.9	1
295	EVALUATION OF THE IN VITRO ACTIVITY OF CEFTAROLINE AND COMPARATORS AGAINST STREPTOCOCCUS PNEUMONIAE ISOLATES FROM THE UNITED STATES: RESULTS FROM 10 YEARS OF THE AWARE SURVEILLANCE PROGRAM (2011-2020). Chest, 2021, 160, A513.	0.8	1
296	Regional pooling of national data from a small number of sites can be misleading: maybe yes? But data can be complimentary to other studies and valuable to infectious disease physicians!. Diagnostic Microbiology and Infectious Disease, 2014, 80, 91-92.	1.8	0
297	116. Critical Care Medicine, 2014, 42, A1388.	0.9	0
298	ANTIMICROBIAL ACTIVITY OF DALBAVANCIN AGAINST GRAM-POSITIVE BACTERIA ISOLATED FROM PATIENTS WITH INFECTIVE ENDOCARDITIS FROM THE UNITED STATES AND EUROPE (2016-2020): RESULTS FROM THE INTERNATIONAL DALBAVANCIN EVALUATION OF ACTIVITY (IDEA) PROGRAM. Chest, 2021, 160, A510.	0.8	0